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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S63Conclusions: A change in the RNA decay rates of COL2A1, DKK1 and
ADAMTS5, conferred by the ageing process, may be accountable for the
differential gene expression observed for these genes in RNASeq studies
of healthy equine articular cartilage. Altered gene expression previously
identiﬁed following RNASeq studies of the other genes examined here is
probably under control of different mechanisms.
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FRAILTY SYNDROME IN THE COMMUNITY DWELLING ELDERLYWITH
OSTEOARTHRITIS
R.C. Miguel, R.C. Dias, J.D. Dias, S.L. Silva, T.M. Ribeiro. UFMG, Belo
Horizonte, Brazil
Purpose: the aim of this study was to characterize and compare com-
munity-dwelling elderly people with knee and/or hip osteoarthritis
according to the presence of frailty syndrome.
Methods: A cross-sectional study was carried out to evaluate socio-
demographic characteristics, comorbidity, depression, anthropomorphic
data,subjective evaluations of health, falls, pain,stiffness,physical func-
tion and frailty (Fried phenotype)in elderly subjectswith osteoarthritis of
the knee and hip using a subsample from FIBRA (a study of frailty in
Brazilian elderly people).
Results: The ﬁnal sample consisted of 58 elderly people with an average
age of 74 (5.5). 17 (29.31%) were classiﬁed as non-frail (NF) 28(48.28%)
as pre-frail (PF) and 13 (22.41%) as frail(F). F group used more medi-
cations (7.00  2.00) than NF group (4.00  2.00), (p ¼ 0.001). The BMI
(Body Mass Index) was lower for the elderly in NF group (average of
27.00 4.50 Kg/m2) compared to PF group (average of 30.00  4.00 Kg/
m2) and F group (average of 34.00 8.00 Kg/m2), (p¼ 0.018). History of
depression was more prevalent in frailty group. When comparing the
subjects health with the situation one year before, a difference was
found between the groups (p ¼ 0.016). The majority of the elderly in PF
Group (64.3%) believed that their health had deteriorated compared to
46.2% of F Group and in NF group 52.9% believed that their health was
unchanged. When present levels of physical activity were compared
with those one year before, PF and F Groups considered that the present
level was worse (p ¼ 0.010). In the case of function, it was found that F
Group was worse than the others (p ¼ 0.023), and the same was found
for fall related self-efﬁcacy (p ¼ 0.017).There were no signiﬁcant dif-
ferences between the groups for the remainder of the items analyzed.
Conclusions: The elderly with osteoarthritis and frailty use more
medications, were more obese, suffered more depression, have less fall
related self-efﬁcacy and worse physical function, as well as a poorer
perception of their own health and their level of activity in comparison
with the previous year. These characteristics may have a negative
impact on their quality of life and demand the attention of health
professionals.ANOVA
Not
corrected
Corrected for biomarkers
and OA and demographic
variables
P P
WO MAC A-pain
Fasitibant 1 mg versus placebo 0.968 0.8188
Fasitibant 2.5 mg versus placebo 0.238 0.2822
Fasitibant 5 mg versus placebo 0.624 0.0970
WOMAC B-stiffness
Fasitibant 1 mg versus placebo 0.860 0.0554
Fasitibant 2.5 mg versus placebo 0.210 0.0233
Fasitibant 5 mg versus placebo 0.677 0.9220
WOMAC C-function
Fasitibant 1 mg versus placebo 0.934 0.0252
Fasitibant 2.5 mg versus placebo 0.049 0.0015
Fasitibant 5 mg versus placebo 0.943 0.8225
WOMAC Overall index
Fasitibant 1 mg versus placebo 0.897 0.0341
Fasitibant 2.5 mg versus placebo 0.049 0.0026
Fasitibant 5 mg versus placebo 0.927 0.7680Biomarkers
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SERUM BIOMARKERS DETECTION CLUSTERS IMPROVE THE
DETECTION OF SYMPTOMATIC TREATMENT EFFECT IN KNEE
OSTEOARTHITIS PATIENTS: THE RESULTS OF A PHASE IB/IIA STUDY
WITH THE B2 RECEPTOR ANTAGONIST FASITIBANT
S. Meini, F. Bellucci, P. Cucchi, C. Catalani, A. Nizzardo, C. Rossi,
A. Capriati, C.A. Maggi. Menarini Ricerche S.p.A., Florence, Italy
Purpose: The correlation between the clinical outcome and a panel of
serum biomarkers indicative of inﬂammation or cartilage catabolism
was investigated in a Phase IB/IIA clinical study, in which the analgesic
activity of the bradykinin (BK) B2 receptor antagonist fasitibant was
evaluated in knee osteoarthritis (KOA).
Methods: 36 patients with KOA received a single intra-articular placebo
or fasitibant dose of 1, 2.5, or 5 mg. Before and 7  2 days after treat-
ment, patients were asked to assign the WOMAC scores and a blood
sample was collected for measuring 22 OA biomarkers in serum (COMP,
keratan sulphate, aggrecan, glycosaminoglycans, CTX-II, hyaluronic acid
(HA), CRP, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1, TIMP-2,
eotaxin-2, IL-6, IL-15, IL-17, IL-18, VEGF, uric acid) and in the plasma
(BK) by using EIA and colorimetric assays. Absolute changes of bio-
markers were ANOVA analysed as dependent variable in function of the
treatments; in addition, changes (%) of biomarkers were included as
covariate in the ANOVA analysis for the evaluation of the WOMAC A-
pain, B-stiffness and C functional subscores, and the overall score.Results: The variance of biomarkers changes , as dependent variable,
was signiﬁcant (P<0.05) for BK, COMP, CRP, HA, MMP-2, MMP-3,
MMP-9, TIMP-1, TIMP-2, eotaxin VEGF, and uric acid. On the other
hand, basal biomarker concentrations or treatment, as covariates,
signiﬁcantly accounted for the changes of BK, COMP, CRP, eotaxin, HA,
MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, VEGF and uric acid
levels. MMP-2 was statistically signiﬁcant lower in the OA group
treated with 1 mg (p ¼ 0.0533) and 2.5 mg (p ¼ 0.0079) of fasitibant
versus placebo; TIMP-2 approached only the statistical signiﬁcance
due the a level adjustment (p ¼ 0.0209 for 1 mg and p ¼ 0.0651 for
2.5 mg).
ANOVA models on pain score in function of treatment (with basal
pain score, biomarkers change and their interaction with the treat-
ment as covariate) were applied to select those biomarkers which
better explain the pain clinical outcome, namely CTX-II (p ¼ 0.0150),
TIMP-1 (p ¼ 0.0076), TIMP-2 (p ¼ 0.0170), basal BK (p ¼ 0.0386 and p
¼ 0.0466), MMP-9, HA, and eotaxin (nearly signiﬁcant). A factor
analysis was then applied to cluster the selected biomarkers, demo-
graphics (BMI, age and sex) and OA related variables (onset time,
effusion, and knee circumference);then by using a stepwise proce-
dure, WOMAC A, B, and C subscores, and the overall score were
analysed in function of the grouped biomarkers (factor 1: CTX-II, HA,
TIMP-2, BK; factor 2: MMP-9, eotaxin-2, TIMP-2) and grouped OA and
demographic variables, and in function of the relative baseline
WOMAC score, the visit and the treatment. None of the covariated
factors had a signiﬁcant inﬂuence on the variance of WOMAC A-pain
and B-stiffness in the fasitibant versus placebo treated groups, and
post hoc test (Student t test) following the ANOVA analysis did not
highlight signiﬁcant differences. Nevertheless the correction by bio-
markers factor 1 and OA and demographic factor 1(BMI and knee
circumference) contributed to render statistically signiﬁcant the dif-
ference in WOMAC B-stiffness favouring fasitibant 2.5 mg over
placebo.
Statistically signiﬁcant results were also obtained when WOMAC C-
function score or overall index were considered as dependent variables.
Either demographic, OA characteristics, and differences in changes of
MMP-9, eotaxin, and TMP-2 signiﬁcantly reduced the residual variance
of the model. Moreover, higher difference, and consequently higher
statistical signiﬁcance favouring fasitibant 1mg and 2.5mg over placebo
occurred.
Conclusions: The present exploratory investigation suggests the cor-
relation between osteoarthritis biomarkers (reaching statistical sig-
niﬁcance for MMP-2, TIMP-2) and the symptomatic clinical outcome in
patients one week after a pharmacological treatment with fasitibant
belonging to the novel class of BK B2 receptor antagonist. Moreover, the
study indicates that eotaxin, MMP-9, and TIMP are able to correct and
improve the detection of fasitibant clinical beneﬁt over placebo meas-
ured by WOMAC score.
